Scale Biosciences

Scale Biosciences is a private, commercial-stage platform company based in San Diego, founded in 2017. It has developed the QuantumScale platform, powered by its proprietary Quantum Barcoding technology, which offers an instrument-free, highly flexible solution for single-cell RNA-seq, ATAC-seq, and methylation profiling. The company is positioned as a disruptive force in the single-cell genomics market, competing with established players like 10x Genomics, and has recently entered into an acquisition agreement with 10x Genomics. Its business model is based on selling consumable kits and related services to academic, biopharma, and clinical researchers.

Quantum Barcoding Technology: A next-generation, instrument-free combinatorial indexing method for single-cell analysis that uses uniquely barcoded beads and plate-based workflows to enable massively parallel processing of samples (from 10s to 1,000s) and cells (from hundreds to millions). It supports multi-omic applications including RNA-seq, ATAC-seq, and methylation profiling.

Scale Bio competes in the high-growth single-cell genomics tools market. Its main competitors include 10x Genomics (its acquirer), Parse Biosciences, Singleron, Becton Dickinson, and others offering droplet- or plate-based solutions. Scale's key differentiator is its combination of extreme scalability, instrument-independence, and cost-effectiveness, positioning it as a disruptive force for large-scale studies.